# Sermorelin: GHRH(1-29) Secretagogue Research Brief > Sermorelin is GHRH(1-29), the 29-amino-acid fragment that tells the pituitary to release its own growth hormone. A cited brief on the mechanism, pharmacokinetics, and how it compares to ipamorelin, CJC-1295, and tesamorelin. A cited research brief on the GHRH-receptor mechanism, the ~10-12 minute plasma half-life, and how the native fragment reads against ipamorelin, CJC-1295, and tesamorelin. The evidence is graded before the verdict. ## The short version **Sermorelin** is a lab-made copy of the first 29 amino acids of GHRH (the brain's own "make growth hormone" signal). It is a secretagogue (something that tells a gland to release its hormone): instead of injecting growth hormone itself, sermorelin nudges the pituitary — a small gland under the brain — to release the body's own GH in natural bursts. Higher GH then raises IGF-1 (a growth signal the liver makes when GH rises). It was once an approved prescription drug for children who could not grow; today it is prepared by compounding pharmacies and studied in the lab. This page summarizes what the published studies measured, with every number cited. ## What the sermorelin literature establishes Sermorelin is the amino-terminal 1-29 fragment of growth hormone-releasing hormone, and it is the shortest fragment that keeps the full activity of the 44-amino-acid parent hormone [1]. It binds GHRH receptors on the pituitary's growth-hormone cells and prompts those cells to release growth hormone in the body's own pulsatile (bursty, not steady-drip) rhythm. The clinical record is older and deeper than most research peptides. In growth-hormone-deficient children, once-daily subcutaneous GHRH(1-29) raised first-year height velocity from roughly 4.1 cm/year to about 7-8 cm/year, without generating excessive IGF-1 [1]. In healthy older men, 0.5 mg and 1 mg twice daily for 14 days produced dose-related rises in 24-hour growth hormone and IGF-1; after the high-dose course, their GH and IGF-1 measures no longer differed from those of young men [2]. The pharmacokinetics are fast. Intravenous GHRH(1-29)NH2 triggered measurable GH release at doses as low as 0.25 mcg/kg, with maximal release at 1-2 mcg/kg; the peptide is cleared from plasma within minutes, yet a single dose kept serum growth hormone elevated for about 3 hours [3]. That brevity — a [sermorelin half-life](/research) on the order of 10-12 minutes — is the engineering problem every longer-acting analog in this catalog was built to solve. What the literature does **not** yet establish is a long-term adult anti-aging benefit. An Annals of Internal Medicine editorial judged the use of growth hormone secretagogues to slow aging "not yet ready for prime time" [5]. This brief follows that line: it reports what was measured and flags where the data stops. ## Sermorelin peptide: GHRH(1-29) structure and identity The **sermorelin peptide** is a synthetic 29-amino-acid chain — the N-terminal 1-29 segment of human GHRH — with an amide cap on its tail end, supplied as the acetate salt [1]. Its molecular weight is 3357.9 Da and its CAS number is 86168-78-7. Because it reproduces only the active fragment rather than the whole 44-residue hormone, it is the most economical structure that still switches on the GHRH receptor at full strength. The single design constraint is stability. The native fragment is rapidly broken down in plasma, which is why researchers later substituted a D-amino acid at position 2: incorporating D-Ala2 into GHRH(1-29)NH2 increased the peptide's half-life and reduced its metabolic clearance in healthy men [7]. That structure-activity insight is the bridge from sermorelin to the long-acting analogs covered on the [sermorelin vs CJC-1295](/sermorelin-vs-cjc-1295) page. ## Sermorelin mechanism of action: GHRH-receptor signaling on somatotrophs **Sermorelin mechanism of action** begins at the GHRH receptor (a class B G-protein-coupled receptor) on somatotrophs — the growth-hormone-producing cells of the anterior pituitary. Binding activates the Gs / adenylate cyclase / cAMP / protein kinase A pathway, raising cyclic AMP inside the cell and triggering both the synthesis and the pulsatile release of growth hormone [1]. The defining feature is what sermorelin does *not* override. Because it acts upstream — telling the gland to release its own hormone rather than supplying hormone from outside — the body's natural brakes stay connected. Somatostatin (the hypothalamic "stop" signal) and IGF-1 negative feedback both remain operative, so the GH that follows arrives in the normal bursty pattern rather than as a flat, continuous level. An editorial argues this is a more physiologic route to adult-onset growth-hormone insufficiency than recombinant GH, precisely because feedback and pulsatility are preserved [4]. The pattern of delivery matters too: in normal men, pulsatile GHRH delivery preserved the GH response better than a continuous infusion [12]. ## Sermorelin and endogenous growth hormone release The link to **sermorelin growth hormone** output is direct: the compound exists to raise the body's own GH, and the downstream IGF-1 that GH drives. In healthy older men, twice-daily GHRH(1-29) for 14 days reversed the age-related decline in both GH and IGF-1 at the high dose, with no change in fasting glucose [2]. Growth hormone is itself secreted in pulses, concentrated during slow-wave sleep, and the axis is self-limiting: GH exerts autofeedback on its own response to GHRH, modulated by free fatty acids and somatostatin [13]. A 2025 Nature Reviews Endocrinology review synthesizes this biology — GHRH-receptor signaling, the GH/IGF-1 axis, and the therapeutic use of GHRH agonists and antagonists — across health and disease [14]. The regulation is multifactorial; a separate review catalogs the roles of ghrelin, klotho, and nesfatins in shaping GH secretion [15]. ## The honest gaps Two cautions sit at the front of this brief, not buried in it. First, the marketing outpaces the evidence: sermorelin is widely promoted for adult anti-aging and body-composition benefit, but rigorous long-term efficacy and safety data for that use are limited, and the most-cited editorial on the question is explicitly skeptical [5]. Second, because GH and IGF-1 are mitogenic — they push cells to divide — chronically raising them is theorized to carry an oncologic consideration that applies to any GH-axis intervention, even one that works through the body's own feedback-regulated secretion. The [reported side effects](/research) and the regulatory standing are covered in full on the page that lays out [what the research shows](/research). For how the native fragment reads against other secretagogues, start with [sermorelin vs ipamorelin](/sermorelin-vs-ipamorelin); for the question index, see the [frequently asked questions](/faq); and every figure here resolves to the [full reference list](/references). --- A confidence-graded intelligence brief on the GHRH(1-29) secretagogue record — each figure scored against its study, the pediatric-growth evidence held apart from the limited adult anti-aging data and the formerly-approved-now-compounded status stated plainly; no clinic behind the console and nothing here dosed, prescribed, or sold.